

## Sepsis: Short Lectures by Tom van der Poll and Joost Wiersinga (Amsterdam UMC)




**Tom van der Poll, MD, PhD**  
**Professor of Medicine and Chair, Department of Medicine, Amsterdam UMC**

Van der Poll is a clinician–scientist specializing in sepsis, pneumonia, and host–pathogen interactions. His research focuses on immune responses to severe infections and the role of coagulation and inflammation.

### ***“How to quantify the dysregulated host response in sepsis and implications for immunotherapy?”***

Sepsis is a dysregulated host response to infection resulting in life-threatening organ failure. Although immune dysregulation is central to the sepsis definition, immunomodulation trials enroll participants based on clinical severity, not the extent of dysregulation, which could contribute to treatment heterogeneity. This lecture will discuss ways to characterize and quantify immune dysregulation. A pragmatic way to quantify immune dysregulation in patients with sepsis could improve prognostication, help to evaluate treatment responses, and identify individuals most likely to benefit from immunomodulation.



**W. Joost Wiersinga, MD, PhD, MBA**  
**Professor of Medicine and Chair, Division of Infectious Diseases, Amsterdam UMC**

Wiersinga is a clinician–scientist specializing in sepsis and severe infections. His research focuses on host responses, pneumonia, melioidosis, and the gut microbiome.

### ***“The gut microbiome in sepsis”***

Sepsis is associated with profound and continuous disruption of the gut microbiome, driven by both the underlying disease and iatrogenic interventions, contributing to adverse outcomes such as ventilator-associated pneumonia, reinfection, and readmission. Although microbiome alterations are increasingly recognized, clinical strategies do not yet target these disruptions. This lecture will discuss mechanisms of microbiome disruption, including loss of beneficial anaerobes, impaired metabolite signaling, and expansion of opportunistic pathogens. A translational approach to characterize and restore microbiome function may improve outcomes and guide development of microbiome-based therapies in sepsis.

The event will be held in English in a hybrid format (on-site & Zoom) at 6:00 p.m. in the lounge on the first floor of Building 3 (South Wing).午後6時より3号館（南棟）1階ラウンジとZoomにて行われます。Zoom link: <https://x.gd/Tvn4B>

Contact: Department of Infectious Diseases Namkoong, Fujikawa Ext.61161 [riefujikawa@keio.jp](mailto:riefujikawa@keio.jp)

